Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.
FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
In a town where the main business is politics, the election of a new president heightens the intensity.
Dr. Stephen Ostroff took over as the FDA’s acting commissioner when Dr. Margaret Hamburg stepped down in March.
Perhaps the best testament to Commissioner Hamburg’s tenure is that crises were uniformly handled responsibly
The more clarity that FDA provides, the more confident companies can be in their medical communications
Major provisions in the FDA Safety and Innovation Act could make the approval process more transparent
Get the most out of
Register for free and enjoy unlimited access to: